JPWO2020052688A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020052688A5 JPWO2020052688A5 JP2021514039A JP2021514039A JPWO2020052688A5 JP WO2020052688 A5 JPWO2020052688 A5 JP WO2020052688A5 JP 2021514039 A JP2021514039 A JP 2021514039A JP 2021514039 A JP2021514039 A JP 2021514039A JP WO2020052688 A5 JPWO2020052688 A5 JP WO2020052688A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- fluoro
- isopropyl
- imidazo
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 229920006395 saturated elastomer Polymers 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 13
- 230000008499 blood brain barrier function Effects 0.000 claims description 12
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 238000001959 radiotherapy Methods 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- 229930192392 Mitomycin Natural products 0.000 claims description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 3
- 229940034982 antineoplastic agent Drugs 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 3
- 229960002707 bendamustine Drugs 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 3
- 229960005243 carmustine Drugs 0.000 claims description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 3
- 229960004630 chlorambucil Drugs 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 3
- 229960001101 ifosfamide Drugs 0.000 claims description 3
- 229960004768 irinotecan Drugs 0.000 claims description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 3
- 229960001924 melphalan Drugs 0.000 claims description 3
- 229960004857 mitomycin Drugs 0.000 claims description 3
- -1 nitro, hydroxyl Chemical group 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
- CCPABWZMHLKHOU-UHFFFAOYSA-N 7-fluoro-3-methyl-1-propan-2-yl-8-[6-(2-pyrrolidin-1-ylethoxymethyl)pyridin-3-yl]imidazo[4,5-c]cinnolin-2-one Chemical compound C1(F)=C(C2=CN=C(C=C2)COCCN2CCCC2)C=C2C=3N(C(=O)N(C=3N=NC2=C1)C)C(C)C CCPABWZMHLKHOU-UHFFFAOYSA-N 0.000 claims description 2
- UNCGOLKXUDKPKS-UHFFFAOYSA-N 7-fluoro-3-methyl-1-propan-2-yl-8-[6-(3-pyrrolidin-1-ylpropoxy)pyridin-3-yl]imidazo[4,5-c]cinnolin-2-one Chemical compound FC1=C(C2=CN=C(OCCCN3CCCC3)C=C2)C=C2C=3N(C(=O)N(C=3N=NC2=C1)C)C(C)C UNCGOLKXUDKPKS-UHFFFAOYSA-N 0.000 claims description 2
- DCCDYBCUHXTDSC-UHFFFAOYSA-N 7-fluoro-3-methyl-8-[6-(2-morpholin-4-ylethoxymethyl)pyridin-3-yl]-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound FC=1C(=CC=2C3=C(N=NC=2C=1)N(C(N3C(C)C)=O)C)C=1C=NC(=CC=1)COCCN1CCOCC1 DCCDYBCUHXTDSC-UHFFFAOYSA-N 0.000 claims description 2
- TYZAHWGVMYFMBR-UHFFFAOYSA-N 7-fluoro-3-methyl-8-[6-(2-piperazin-1-ylethoxymethyl)pyridin-3-yl]-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound FC=1C(=CC=2C3=C(N=NC=2C=1)N(C(N3C(C)C)=O)C)C=1C=NC(=CC=1)COCCN1CCNCC1 TYZAHWGVMYFMBR-UHFFFAOYSA-N 0.000 claims description 2
- ZEOACOGRBZQJJQ-UHFFFAOYSA-N 7-fluoro-3-methyl-8-[6-(2-piperidin-1-ylethoxymethyl)pyridin-3-yl]-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound FC1=C(C2=CN=C(C=C2)COCCN2CCCCC2)C=C2C=3N(C(=O)N(C=3N=NC2=C1)C)C(C)C ZEOACOGRBZQJJQ-UHFFFAOYSA-N 0.000 claims description 2
- GIUQJDQSFVEXFY-UHFFFAOYSA-N 7-fluoro-3-methyl-8-[6-(3-morpholin-4-ylpropoxy)pyridin-3-yl]-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound FC=1C(=CC=2C3=C(N=NC=2C=1)N(C(N3C(C)C)=O)C)C=1C=NC(=CC=1)OCCCN1CCOCC1 GIUQJDQSFVEXFY-UHFFFAOYSA-N 0.000 claims description 2
- YAKKZOPXKUUTNR-UHFFFAOYSA-N 7-fluoro-3-methyl-8-[6-(3-piperazin-1-ylpropoxy)pyridin-3-yl]-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound FC=1C(=CC=2C3=C(N=NC=2C=1)N(C(N3C(C)C)=O)C)C=1C=NC(=CC=1)OCCCN1CCNCC1 YAKKZOPXKUUTNR-UHFFFAOYSA-N 0.000 claims description 2
- HONSNEDYRQWJPQ-UHFFFAOYSA-N 7-fluoro-3-methyl-8-[6-[2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethoxymethyl]pyridin-3-yl]-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound C1OCC11CN(C1)CCOCC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C HONSNEDYRQWJPQ-UHFFFAOYSA-N 0.000 claims description 2
- DHZMCFVDHAUXMV-UHFFFAOYSA-N 7-fluoro-3-methyl-8-[6-[2-(4-methylpiperazin-1-yl)ethoxymethyl]pyridin-3-yl]-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound FC=1C(=CC=2C3=C(N=NC=2C=1)N(C(N3C(C)C)=O)C)C=1C=NC(=CC=1)COCCN1CCN(CC1)C DHZMCFVDHAUXMV-UHFFFAOYSA-N 0.000 claims description 2
- PVEAQAXOZICBCB-UHFFFAOYSA-N 7-fluoro-3-methyl-8-[6-[3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)propoxy]pyridin-3-yl]-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound C1OCC11CN(C1)CCCOC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C PVEAQAXOZICBCB-UHFFFAOYSA-N 0.000 claims description 2
- SZWAOZFEAGDCSW-UHFFFAOYSA-N 7-fluoro-3-methyl-8-[6-[3-(4-methylpiperazin-1-yl)propoxy]pyridin-3-yl]-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound FC=1C(=CC=2C3=C(N=NC=2C=1)N(C(N3C(C)C)=O)C)C=1C=NC(=CC=1)OCCCN1CCN(CC1)C SZWAOZFEAGDCSW-UHFFFAOYSA-N 0.000 claims description 2
- ODTOPIDGJZLIEA-UHFFFAOYSA-N 7-fluoro-8-[6-[2-(4-fluoropiperidin-1-yl)ethoxymethyl]pyridin-3-yl]-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound FC=1C(=CC=2C3=C(N=NC=2C=1)N(C(N3C(C)C)=O)C)C=1C=NC(=CC=1)COCCN1CCC(CC1)F ODTOPIDGJZLIEA-UHFFFAOYSA-N 0.000 claims description 2
- XQILLFFLOKQCIG-QGZVFWFLSA-N 7-fluoro-8-[6-[2-[(3R)-3-fluoropyrrolidin-1-yl]ethoxymethyl]pyridin-3-yl]-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound FC=1C(=CC=2C3=C(N=NC=2C=1)N(C(N3C(C)C)=O)C)C=1C=NC(=CC=1)COCCN1C[C@@H](CC1)F XQILLFFLOKQCIG-QGZVFWFLSA-N 0.000 claims description 2
- IAWLWEIRGGUDTG-UHFFFAOYSA-N 7-fluoro-8-[6-[3-(4-fluoropiperidin-1-yl)propoxy]pyridin-3-yl]-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound FC=1C(=CC=2C3=C(N=NC=2C=1)N(C(N3C(C)C)=O)C)C=1C=NC(=CC=1)OCCCN1CCC(CC1)F IAWLWEIRGGUDTG-UHFFFAOYSA-N 0.000 claims description 2
- BTKVAQIEQCVAIF-QGZVFWFLSA-N 7-fluoro-8-[6-[3-[(3R)-3-fluoropyrrolidin-1-yl]propoxy]pyridin-3-yl]-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound FC=1C(=CC=2C3=C(N=NC=2C=1)N(C(N3C(C)C)=O)C)C=1C=NC(=CC=1)OCCCN1C[C@@H](CC1)F BTKVAQIEQCVAIF-QGZVFWFLSA-N 0.000 claims description 2
- BTKVAQIEQCVAIF-KRWDZBQOSA-N 7-fluoro-8-[6-[3-[(3S)-3-fluoropyrrolidin-1-yl]propoxy]pyridin-3-yl]-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound FC=1C(=CC=2C3=C(N=NC=2C=1)N(C(N3C(C)C)=O)C)C=1C=NC(=CC=1)OCCCN1C[C@H](CC1)F BTKVAQIEQCVAIF-KRWDZBQOSA-N 0.000 claims description 2
- FWEGZXVOHJHGBC-UHFFFAOYSA-N 8-[6-[2-(2-azaspiro[3.3]heptan-2-yl)ethoxymethyl]pyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound C1N(CC11CCC1)CCOCC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C FWEGZXVOHJHGBC-UHFFFAOYSA-N 0.000 claims description 2
- LRLFYYXKMQFEMF-UHFFFAOYSA-N 8-[6-[2-(3-azabicyclo[3.1.0]hexan-3-yl)ethoxymethyl]pyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound C12CN(CC2C1)CCOCC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C LRLFYYXKMQFEMF-UHFFFAOYSA-N 0.000 claims description 2
- VSFKZXPUYPRRII-UHFFFAOYSA-N 8-[6-[2-(4-cyclopropylpiperazin-1-yl)ethoxymethyl]pyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound C1(CC1)N1CCN(CC1)CCOCC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C VSFKZXPUYPRRII-UHFFFAOYSA-N 0.000 claims description 2
- IDNUGDIHZPUFNV-UHFFFAOYSA-N 8-[6-[2-(6-azabicyclo[3.2.0]heptan-6-yl)ethoxymethyl]pyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound C12CCCC2N(C1)CCOCC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C IDNUGDIHZPUFNV-UHFFFAOYSA-N 0.000 claims description 2
- SDNSUKXTUQUVEK-UHFFFAOYSA-N 8-[6-[2-(diethylamino)ethoxymethyl]pyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound C(C)N(CCOCC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C)CC SDNSUKXTUQUVEK-UHFFFAOYSA-N 0.000 claims description 2
- QKRLOASRBKEUND-UHFFFAOYSA-N 8-[6-[2-(dimethylamino)ethoxymethyl]pyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound CN(CCOCC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C)C QKRLOASRBKEUND-UHFFFAOYSA-N 0.000 claims description 2
- BUJMFUGHAASTKK-UHFFFAOYSA-N 8-[6-[2-[ethyl(methyl)amino]ethoxymethyl]pyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound C(C)N(CCOCC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C)C BUJMFUGHAASTKK-UHFFFAOYSA-N 0.000 claims description 2
- VTKIBPPEYRNZRK-UHFFFAOYSA-N 8-[6-[3-(2-azaspiro[3.3]heptan-2-yl)propoxy]pyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound C1N(CC11CCC1)CCCOC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C VTKIBPPEYRNZRK-UHFFFAOYSA-N 0.000 claims description 2
- ZAKWFUKOHGBXKM-UHFFFAOYSA-N 8-[6-[3-(2-azaspiro[3.4]octan-2-yl)propoxy]pyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound C1N(CC11CCCC1)CCCOC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C ZAKWFUKOHGBXKM-UHFFFAOYSA-N 0.000 claims description 2
- SSPRJXNUFWSIDY-UHFFFAOYSA-N 8-[6-[3-(3-azabicyclo[3.1.0]hexan-3-yl)propoxy]pyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound C12CN(CC2C1)CCCOC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C SSPRJXNUFWSIDY-UHFFFAOYSA-N 0.000 claims description 2
- ZVDAUYGPQLIGSS-UHFFFAOYSA-N 8-[6-[3-(4-cyclopropylpiperazin-1-yl)propoxy]pyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound C1(CC1)N1CCN(CC1)CCCOC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C ZVDAUYGPQLIGSS-UHFFFAOYSA-N 0.000 claims description 2
- URUWFSJGHRSZRG-UHFFFAOYSA-N 8-[6-[3-(6-azabicyclo[3.2.0]heptan-6-yl)propoxy]pyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound C12CCCC2N(C1)CCCOC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C URUWFSJGHRSZRG-UHFFFAOYSA-N 0.000 claims description 2
- IOTYLGDBUWBMMT-UHFFFAOYSA-N 8-[6-[3-(diethylamino)propoxy]pyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound C(C)N(CCCOC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C)CC IOTYLGDBUWBMMT-UHFFFAOYSA-N 0.000 claims description 2
- DZJKYNYWKOYGFY-UHFFFAOYSA-N 8-[6-[3-(dimethylamino)propoxy]-2-fluoropyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound CN(CCCOC1=CC=C(C(=N1)F)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C)C DZJKYNYWKOYGFY-UHFFFAOYSA-N 0.000 claims description 2
- AMVIOMPGDDKABN-UHFFFAOYSA-N 8-[6-[3-[(dimethylamino)methyl]pyrrolidin-1-yl]pyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound CN(C)CC1CN(CC1)C1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C AMVIOMPGDDKABN-UHFFFAOYSA-N 0.000 claims description 2
- VNKMOFIWPQLROW-UHFFFAOYSA-N 8-[6-[3-[ethyl(methyl)amino]propoxy]pyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound C(C)N(CCCOC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C)C VNKMOFIWPQLROW-UHFFFAOYSA-N 0.000 claims description 2
- GFGRHEYDSLFDPV-UHFFFAOYSA-N 8-[6-[4-(dimethylamino)piperidin-1-yl]pyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound CN(C1CCN(CC1)C1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C)C GFGRHEYDSLFDPV-UHFFFAOYSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- HVWMSPQYCHJIEG-UHFFFAOYSA-N CN(CCCOC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C)C Chemical compound CN(CCCOC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C)C HVWMSPQYCHJIEG-UHFFFAOYSA-N 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- ZWYURCOBOJCSAR-UHFFFAOYSA-N FC=1C(=CC=2C3=C(N=NC=2C=1)N(C(N3C(C)C)=O)C)C=1C=NC(=CC=1)OCCCN1CCCCC1 Chemical compound FC=1C(=CC=2C3=C(N=NC=2C=1)N(C(N3C(C)C)=O)C)C=1C=NC(=CC=1)OCCCN1CCCCC1 ZWYURCOBOJCSAR-UHFFFAOYSA-N 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000005945 translocation Effects 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- MYKSPFTYAVPGOY-UHFFFAOYSA-N 7-fluoro-3-methyl-1-(oxan-4-yl)-8-[6-(3-piperidin-1-ylpropoxy)pyridin-3-yl]imidazo[4,5-c]cinnolin-2-one Chemical compound FC=1C(=CC=2C3=C(N=NC=2C=1)N(C(N3C1CCOCC1)=O)C)C=1C=NC(=CC=1)OCCCN1CCCCC1 MYKSPFTYAVPGOY-UHFFFAOYSA-N 0.000 description 1
- DGESEVCZNQHEPD-UHFFFAOYSA-N 7-fluoro-3-methyl-1-(oxan-4-yl)-8-[6-(3-pyrrolidin-1-ylpropoxy)pyridin-3-yl]imidazo[4,5-c]cinnolin-2-one Chemical compound FC=1C(=CC=2C3=C(N=NC=2C=1)N(C(N3C1CCOCC1)=O)C)C=1C=NC(=CC=1)OCCCN1CCCC1 DGESEVCZNQHEPD-UHFFFAOYSA-N 0.000 description 1
- MUMJEMFQAQJQMO-UHFFFAOYSA-N 7-fluoro-8-[6-[3-(4-fluoropiperidin-1-yl)propoxy]pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]cinnolin-2-one Chemical compound FC=1C(=CC=2C3=C(N=NC=2C=1)N(C(N3C1CCOCC1)=O)C)C=1C=NC(=CC=1)OCCCN1CCC(CC1)F MUMJEMFQAQJQMO-UHFFFAOYSA-N 0.000 description 1
- FYUXTAVOLODVAU-GOSISDBHSA-N 7-fluoro-8-[6-[3-[(3R)-3-fluoropyrrolidin-1-yl]propoxy]pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]cinnolin-2-one Chemical compound FC=1C(=CC=2C3=C(N=NC=2C=1)N(C(N3C1CCOCC1)=O)C)C=1C=NC(=CC=1)OCCCN1C[C@@H](CC1)F FYUXTAVOLODVAU-GOSISDBHSA-N 0.000 description 1
- AXZBHWGVOXSGMS-UHFFFAOYSA-N 8-[6-[2-(2-azaspiro[3.4]octan-2-yl)ethoxymethyl]pyridin-3-yl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]cinnolin-2-one Chemical compound C1N(CC11CCCC1)CCOCC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C(C)C)=O)C AXZBHWGVOXSGMS-UHFFFAOYSA-N 0.000 description 1
- KIJDPEMRKGNIGO-UHFFFAOYSA-N 8-[6-[2-(dimethylamino)ethoxymethyl]pyridin-3-yl]-7-fluoro-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]cinnolin-2-one Chemical compound CN(CCOCC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C1CCOCC1)=O)C)C KIJDPEMRKGNIGO-UHFFFAOYSA-N 0.000 description 1
- VBBRGFYIHDIPIX-UHFFFAOYSA-N 8-[6-[3-(dimethylamino)propoxy]pyridin-3-yl]-7-fluoro-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]cinnolin-2-one Chemical compound CN(CCCOC1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C1CCOCC1)=O)C)C VBBRGFYIHDIPIX-UHFFFAOYSA-N 0.000 description 1
- ZQXIUTZVPAVMJX-UHFFFAOYSA-N 8-[6-[3-[(dimethylamino)methyl]pyrrolidin-1-yl]pyridin-3-yl]-7-fluoro-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]cinnolin-2-one Chemical compound CN(C)CC1CN(CC1)C1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C1CCOCC1)=O)C ZQXIUTZVPAVMJX-UHFFFAOYSA-N 0.000 description 1
- BJBRHXDQQASAIF-UHFFFAOYSA-N 8-[6-[4-(dimethylamino)piperidin-1-yl]pyridin-3-yl]-7-fluoro-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]cinnolin-2-one Chemical compound CN(C1CCN(CC1)C1=CC=C(C=N1)C1=CC=2C3=C(N=NC=2C=C1F)N(C(N3C1CCOCC1)=O)C)C BJBRHXDQQASAIF-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
Description
明確さのために別々の実施形態に関連付けられて説明されている、本開示のある特定の特徴は、単一の実施形態において組み合わせて提供もできることは理解される。逆に、簡潔さのために単一の実施形態に関連付けられて説明されている本開示の種々の特徴も、別々に、または任意の好適な部分組合せにおいて、提供することができる。
本発明は以下の通りである。
[1]式(I)の化合物:
(式中、
R
1
は、水素またはメチルであり;
R
2
は、イソプロピルまたはテトラヒドロピラニルであり;
R
3
は、水素またはフルオロであり;
R
4
、R
5
およびR
6
は、それぞれ水素またはフルオロから独立して選択され;
R
7
は-L-NR
8
R
9
であり、Lは直接的な結合、-(CH
2
)
m
O(CH
2
)
n
-、または-CONR
10
(CH
2
)
p
-から選択され、前記-(CH
2
)
m
O(CH
2
)
n
-および前記-CONR
10
(CH
2
)
p
-は場合によっては1または複数のR
11
により置換されていてもよく;
R
8
およびR
9
は、水素、アルキル、アルケニル、アルキニル、飽和または不飽和のシクロアルキル、および飽和または不飽和の複素環式基からなる群からそれぞれ独立して選択され、前記アルキル、アルケニル、アルキニル、飽和または不飽和のシクロアルキル、および飽和または不飽和の複素環式基は場合によっては1または複数のR
12
により置換されていてもよく;あるいは、
R
8
およびR
9
は、それらが結合している窒素原子と一緒になって場合によってはN、O、およびSから選択される1または複数の追加のヘテロ原子を含有していてもよい、且つ、場合によっては1または複数のR
13
により置換されていてもよい飽和または不飽和の複素環式基を形成し;
R
10
は、水素、アルキル、シクロアルキル、および炭素結合した飽和または不飽和の複素環式基からなる群から選択され、前記複素環式基は場合によってはN、O、およびSから選択される1または複数の追加のヘテロ原子を含有していてもよく、且つ、場合によっては1または複数のR
13
により置換されていてもよく;
R
11
は、水素、ハロゲン、アルキル、シクロアルキル、アルコキシル、並びに、場合によってはN、O、およびSから選択される1または複数の追加のヘテロ原子を含有していてもよい、且つ、場合によっては1または複数のR
13
により置換されていてもよい飽和または不飽和の複素環式基からなる群から選択され;
R
12
は、水素、ハロゲン、シアノ、ニトロ、ヒドロキシル、アルキル、アルケニル、アルキニル、およびアルコキシからなる群から選択され;
R
13
は、アシル、アルキル、アルケニル、アルキニル、アルコキシ、アミド、アミノ、アリール、シアノ、シクロアルキル、ハロゲン、ハロアルキル、ハロアルコキシ、ヘテロアリール、ヒドロキシ、ニトロ、および-(CH
2
)
q
NR
14
R
15
からなる群から選択され;
R
14
およびR
15
は、水素、アルキル、およびシクロアルキルからなる群からそれぞれ独立して選択され;あるいは、
R
14
およびR
15
は、それらが結合している窒素原子と一緒になって場合によってはN、O、およびSから選択される1または複数の追加のヘテロ原子を含有していてもよい、且つ、場合によっては1または複数のR
16
により置換されていてもよい飽和または不飽和の複素環式基を形成し;
R
16
は、アシル、アルキル、アルケニル、アルキニル、アルコキシ、アミド、アミノ、アリール、シアノ、シクロアルキル、ハロゲン、ハロアルキル、ハロアルコキシ、ヘテロアリール、ヒドロキシ、およびニトロからなる群から選択され;
mは0、1、または2であり;
nは2~4の範囲の整数であり;
pは2~4の範囲の整数であり;並びに、
qは0、1、または2であり;
ただし、R
2
がテトラヒドロピラン-3-イルであり、且つ、R
3
が水素である場合は、R
7
は-O(CH
2
)
3
N(CH
3
)
2
ではない)。
[2]R
1
がメチルである、上記[1]に記載の式(I)の化合物または薬学的に許容可能なその塩。
[3]R
2
がイソプロピルである、上記[1]に記載の式(I)の化合物または薬学的に許容可能なその塩。
[4]R
3
がフルオロである、上記[1]に記載の式(I)の化合物または薬学的に許容可能なその塩。
[5]R
4
、R
5
、およびR
6
が水素である、上記[1]に記載の式(I)の化合物または薬学的に許容可能なその塩。
[6]R
7
が-L-NR
8
R
9
であり、且つ、Lが直接的な結合である、上記[1]に記載の式(I)の化合物または薬学的に許容可能なその塩。
[7]R
8
およびR
9
が、場合によっては1または複数のR
12
で置換されていてもよいC
1-6
アルキルからそれぞれ独立して選択される、上記[6]に記載の式(I)の化合物または薬学的に許容可能なその塩。
[8]R
8
およびR
9
が、それらが結合している窒素原子と一緒になって:
[9]R
13
がハロゲンである、上記[8]に記載の式(I)の化合物または薬学的に許容可能なその塩。
[10]R
7
が-L-NR
8
R
9
であり、Lが直接的な結合であり、且つ、R
8
およびR
9
がそれらが結合している窒素原子と一緒になって、
[11]R
13
が-(CH
2
)
q
NR
14
R
15
であり、且つ、R
14
およびR
15
がC
1-6
アルキルからそれぞれ独立して選択される、上記[10]に記載の式(I)の化合物または薬学的に許容可能なその塩。
[12]R
7
が-L-NR
8
R
9
であり、Lが-CONR
10
(CH
2
)
p
-であり、R
8
およびR
9
が場合によっては1または複数のR
12
により置換されていてもよいC
1-6
アルキルからそれぞれ独立して選択され、R
10
が水素である、上記[1]に記載の式(I)の化合物または薬学的に許容可能なその塩。
[13]R
1
がメチルであり;
R
2
がイソプロピルであり;
R
3
がフルオロであり;
R
4
、R
5
、およびR
6
が水素であり;
R
7
が-L-NR
8
R
9
であり;
Lが場合によっては1または複数のR
11
により置換されていてもよい-(CH
2
)
m
O(CH
2
)
n
-であり;
R
8
およびR
9
が場合によっては1または複数のR
12
により置換されていてもよいC
1-6
アルキルからそれぞれ独立して選択され;あるいは、
R
8
およびR
9
がそれらが結合している窒素原子と一緒になって、
R
11
が水素であり;
R
12
が水素であり;
R
13
がハロゲンであり;
mが0、1、または2であり;
nが2~4の範囲の整数である、
上記[1]に記載の式(I)の化合物または薬学的に許容可能なその塩。
[14]7-フルオロ-1-イソプロピル-3-メチル-8-(6-(3-(ピペリジン-1-イル)プロポキシ)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(ジメチルアミノ)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-(3-(ピロリジン-1-イル)プロポキシ)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(4-(ジメチルアミノ)ピペリジン-1-イル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-((ジメチルアミノ)メチル)ピロリジン-1-イル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(ジメチルアミノ)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-((2-(ピペリジン-1-イル)エトキシ)メチル)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-((2-(ピロリジン-1-イル)エトキシ)メチル)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
(R)-7-フルオロ-8-(6-((2-(3-フルオロピロリジン-1-イル)エトキシ)メチル)ピリジン-3-イル)-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-8-(6-((2-(4-フルオロピペリジン-1-イル)エトキシ)メチル)ピリジン-3-イル)-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(3-アザビシクロ[3.1.0]ヘキサン-3-イル)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
N-(2-(ジメチルアミノ)エチル)-5-(7-フルオロ-1-イソプロピル-3-メチル-2-オキソ-2,3-ジヒドロ-1H-イミダゾ[4,5-c]シンノリン-8-イル)ピコリンアミド;
7-フルオロ-8-(6-(3-(4-フルオロピペリジン-1-イル)プロポキシ)ピリジン-3-イル)-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
(S)-7-フルオロ-8-(6-(3-(3-フルオロピロリジン-1-イル)プロポキシ)ピリジン-3-イル)-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
(R)-7-フルオロ-8-(6-(3-(3-フルオロピロリジン-1-イル)プロポキシ)ピリジン-3-イル)-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(3-アザビシクロ[3.1.0]ヘキサン-3-イル)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(ジメチルアミノ)プロポキシ)-2-フルオロピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-3-メチル-8-(6-(3-(ピペリジン-1-イル)プロポキシ)ピリジン-3-イル)-1-(テトラヒドロ-2H-ピラン-4-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(ジメチルアミノ)プロポキシ)ピリジン-3-イル)-7-フルオロ-3-メチル-1-(テトラヒドロ-2H-ピラン-4-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-3-メチル-8-(6-(3-(ピロリジン-1-イル)プロポキシ)ピリジン-3-イル)-1-(テトラヒドロ-2H-ピラン-4-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-((ジメチルアミノ)メチル)ピロリジン-1-イル)ピリジン-3-イル)-7-フルオロ-3-メチル-1-(テトラヒドロ-2H-ピラン-4-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(4-(ジメチルアミノ)ピペリジン-1-イル)ピリジン-3-イル)-7-フルオロ-3-メチル-1-(テトラヒドロ-2H-ピラン-4-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(ジメチルアミノ)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-3-メチル-1-(テトラヒドロ-2H-ピラン-4-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-8-(6-(3-(4-フルオロピペリジン-1-イル)プロポキシ)ピリジン-3-イル)-3-メチル-1-(テトラヒドロ-2H-ピラン-4-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
(R)-7-フルオロ-8-(6-(3-(3-フルオロピロリジン-1-イル)プロポキシ)ピリジン-3-イル)-3-メチル-1-(テトラヒドロ-2H-ピラン-4-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(ジエチルアミノ)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(エチル(メチル)アミノ)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-((2-モルホリノエトキシ)メチル)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-((2-(ピペラジン-1-イル)エトキシ)メチル)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-((2-(4-メチルピペラジン-1-イル)エトキシ)メチル)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(4-シクロプロピルピペラジン-1-イル)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(2-アザスピロ[3.3]ヘプタン-2-イル)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(2-オキサ-6-アザスピロ[3.3]ヘプタン-6-イル)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(2-アザスピロ[3.4]オクタン-2-イル)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(6-アザビシクロ[3.2.0]ヘプタン-6-イル)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(ジエチルアミノ)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(エチル(メチル)アミノ)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-(3-モルホリノプロポキシ)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-(3-(ピペラジン-1-イル)プロポキシ)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-(3-(4-メチルピペラジン-1-イル)プロポキシ)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(4-シクロプロピルピペラジン-1-イル)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(2-アザスピロ[3.3]ヘプタン-2-イル)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(2-オキサ-6-アザスピロ[3.3]ヘプタン-6-イル)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(2-アザスピロ[3.4]オクタン-2-イル)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;および
8-(6-(3-(6-アザビシクロ[3.2.0]ヘプタン-6-イル)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン、
からなる群から選択される、上記[1]に記載の式(I)の化合物または薬学的に許容可能なその塩。
[15]ヒト肝サイトゾル系中のタンパク質1mg当たり1.8μL/分未満のAO固有クリアランス値を有する、上記[1]~[14]のいずれかに記載の式(I)の化合物または薬学的に許容可能なその塩。
[16]上記[1]に記載の式(I)の化合物または薬学的に許容可能なその塩および少なくとも1つの薬学的に許容可能な賦形剤を含んでなる、医薬組成物。
[17]血液脳関門(BBB)移行を促進するための薬剤を含まない、上記[16]に記載の医薬組成物。
[18]治療を必要とする対象においてATM関連性疾患または症状を治療する方法であって、上記[1]~[15]のいずれかに記載の式(I)の化合物または薬学的に許容可能なその塩の治療有効量を前記対象に投与することを含んでなる、方法。
[19]前記ATM関連性疾患または症状が癌である、上記[18]に記載の方法。
[20]前記癌が結腸直腸癌、グリア芽腫、胃癌、卵巣癌、びまん性大細胞型B細胞リンパ腫、慢性リンパ性白血病、急性骨髄性白血病、頭頸部扁平上皮癌、乳癌、肝細胞癌、小細胞肺癌、および非小細胞肺癌からなる群から選択される、上記[19]に記載の方法。
[21]前記癌が脳転移などの転移性癌である、上記[19]に記載の方法。
[22]式(I)の化合物または薬学的に許容可能なその塩と同時に、個別に、または逐次に放射線療法を前記対象に施行することをさらに含んでなる、上記[18]に記載の方法。
[23]前記放射線療法が脳照射である、上記[22]に記載の方法。
[24]前記ATM関連性疾患または症状が癌、好ましくはグリア芽腫である、上記[22]または[23]に記載の方法。
[25]治療を必要とする対象においてハンチントン病を治療する方法であって、上記[1]~[15]のいずれかに記載の式(I)の化合物または薬学的に許容可能なその塩の治療有効量を前記対象に投与することを含んでなる、方法。
[26]前記化合物が血液脳関門(BBB)移行を促進するための薬剤の非存在下で血液脳関門(BBB)移行可能である、上記[18]または[25]に記載の方法。
[27]ATM関連性疾患または症状の治療に使用するための、上記[1]~[15]のいずれかに記載の式(I)の化合物または薬学的に許容可能なその塩。
[28]ATM関連性疾患または症状の治療のための医薬の製造における、上記[1]~[15]のいずれかに記載の式(I)の化合物または薬学的に許容可能なその塩の使用。
[29]ATM関連性疾患または症状の治療で使用され、放射線療法と同時に、個別に、または逐次に投与される、上記[1]~[15]のいずれかに記載の式(I)の化合物または薬学的に許容可能なその塩。
[30]ドキソルビシン、イリノテカン、トポテカン、エトポシド、マイトマイシン、ベンダムスチン、クロラムブシル、シクロホスファミド、イホスファミド、カルムスチン、メルファラン、およびブレオマイシンからなる群から選択される少なくとも1種の追加の抗腫瘍薬と同時に、個別に、または逐次に投与される、上記[1]~[15]のいずれかに記載の式(I)の化合物または薬学的に許容可能なその塩。
It is understood that certain features of the disclosure that are described in association with separate embodiments for clarity can also be provided in combination in a single embodiment. Conversely, various features of the disclosure, which are for brevity described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.
The present invention is as follows.
[1] A compound of formula (I):
(In the formula,
R 1 is hydrogen or methyl;
R 2 is isopropyl or tetrahydropyranyl;
R 3 is hydrogen or fluoro;
R 4 , R 5 and R 6 are each independently selected from hydrogen or fluoro;
R 7 is -L-NR 8 R 9 and L is selected from a direct bond, -(CH 2 ) m O(CH 2 ) n -, or -CONR 10 (CH 2 ) p -, said - (CH 2 ) m O(CH 2 ) n — and said —CONR 10 (CH 2 ) p — optionally substituted with one or more R 11 ;
R8 and R9 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl , alkynyl, saturated or unsaturated cycloalkyl, and saturated or unsaturated heterocyclic groups, wherein said alkyl, alkenyl, alkynyl , saturated or unsaturated cycloalkyl, and saturated or unsaturated heterocyclic groups optionally substituted by one or more R 12 ;
R8 and R9 , together with the nitrogen atom to which they are attached, optionally contain one or more additional heteroatoms selected from N, O, and S, and , forming a saturated or unsaturated heterocyclic group optionally substituted by one or more R 13 ;
R 10 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, and carbon-bonded saturated or unsaturated heterocyclic groups, said heterocyclic groups optionally selected from N, O, and S optionally containing one or more additional heteroatoms and optionally substituted by one or more R 13 ;
R 11 may contain hydrogen, halogen, alkyl, cycloalkyl, alkoxyl, and optionally one or more additional heteroatoms selected from N, O, and S, and optionally is selected from the group consisting of saturated or unsaturated heterocyclic groups optionally substituted by one or more R 13 ;
R 12 is selected from the group consisting of hydrogen, halogen, cyano, nitro, hydroxyl, alkyl, alkenyl, alkynyl, and alkoxy;
R 13 is acyl, alkyl, alkenyl, alkynyl, alkoxy, amido, amino, aryl, cyano, cycloalkyl, halogen, haloalkyl, haloalkoxy, heteroaryl, hydroxy, nitro, and —(CH 2 ) q NR 14 R 15 selected from the group consisting of;
R 14 and R 15 are each independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl; or
R 14 and R 15 , together with the nitrogen atom to which they are attached, optionally contain one or more additional heteroatoms selected from N, O, and S, and , forming a saturated or unsaturated heterocyclic group optionally substituted by one or more R 16 ;
R 16 is selected from the group consisting of acyl, alkyl, alkenyl, alkynyl, alkoxy, amido, amino, aryl, cyano, cycloalkyl, halogen, haloalkyl, haloalkoxy, heteroaryl, hydroxy, and nitro;
m is 0, 1, or 2;
n is an integer ranging from 2 to 4;
p is an integer ranging from 2 to 4; and
q is 0, 1, or 2;
with the proviso that when R 2 is tetrahydropyran-3-yl and R 3 is hydrogen, R 7 is not —O(CH 2 ) 3 N(CH 3 ) 2 ).
[2] The compound of formula (I) according to [ 1 ] above, wherein R1 is methyl, or a pharmaceutically acceptable salt thereof.
[3] The compound of formula (I) according to [ 1 ] above, wherein R2 is isopropyl, or a pharmaceutically acceptable salt thereof.
[4] The compound of formula (I) according to [1] above, wherein R3 is fluoro , or a pharmaceutically acceptable salt thereof.
[5] The compound of formula (I) according to [1] above, wherein R 4 , R 5 and R 6 are hydrogen, or a pharmaceutically acceptable salt thereof.
[6] The compound of formula (I) according to [1] above, wherein R 7 is -L-NR 8 R 9 and L is a direct bond, or a pharmaceutically acceptable salt thereof.
[7] Formula (I) according to [6] above, wherein R 8 and R 9 are each independently selected from C 1-6 alkyl optionally substituted with one or more R 12 ) or a pharmaceutically acceptable salt thereof.
[8] R 8 and R 9 together with the nitrogen atom to which they are attached:
[9] The compound of formula (I) according to [8] above, wherein R 13 is halogen, or a pharmaceutically acceptable salt thereof.
[10] R 7 is -L-NR 8 R 9 , L is a direct bond, and R 8 and R 9 together with the nitrogen atom to which they are attached,
[11] R 13 is —(CH 2 ) q NR 14 R 15 and R 14 and R 15 are C 1-6
A compound of formula (I) according to [10] above, or a pharmaceutically acceptable salt thereof, each independently selected from alkyl.
[12] R 7 is -L-NR 8 R 9 , L is -CONR 10 (CH 2 ) p -, and R 8 and R 9 are optionally substituted with one or more R 12 a compound of formula (I) according to [1] above, wherein R 10 is hydrogen , or a pharmaceutically acceptable salt thereof;
[13] R 1 is methyl;
R 2 is isopropyl;
R 3 is fluoro;
R 4 , R 5 , and R 6 are hydrogen;
R 7 is -L-NR 8 R 9 ;
L is —(CH 2 ) m O(CH 2 ) n — optionally substituted with one or more R 11 ;
R 8 and R 9 are each independently selected from C 1-6 alkyl optionally substituted by one or more R 12 ; or
R8 and R9 together with the nitrogen atom to which they are attached,
R 11 is hydrogen;
R 12 is hydrogen;
R 13 is halogen;
m is 0, 1, or 2;
n is an integer ranging from 2 to 4;
A compound of formula (I) or a pharmaceutically acceptable salt thereof according to [1] above.
[14] 7-fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo [4 ,5-c]cinnolin-2-one;
8-(6-(3-(dimethylamino)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnoline -2-on;
7-fluoro-1-isopropyl-3-methyl-8-(6-(3-(pyrrolidin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5- c] cinnolin-2-one;
8-(6-(4-(dimethylamino)piperidin-1-yl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5 -c]cinnolin-2-one;
8-(6-(3-((dimethylamino)methyl)pyrrolidin-1-yl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo [ 4,5-c]cinnolin-2-one;
8-(6-((2-(dimethylamino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5- c] cinnolin-2-one;
7-fluoro-1-isopropyl-3-methyl-8-(6-((2-(piperidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo [4 ,5-c]cinnolin-2-one;
7-fluoro-1-isopropyl-3-methyl-8-(6-((2-(pyrrolidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo [4 ,5-c]cinnolin-2-one;
(R)-7-fluoro-8-(6-((2-(3-fluoropyrrolidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1-isopropyl-3-methyl-1,3- dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
7-fluoro-8-(6-((2-(4-fluoropiperidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H- imidazo[4,5-c]cinnolin-2-one;
8-(6-((2-(3-azabicyclo[3.1.0]hexan-3-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1 ,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
N-(2-(dimethylamino)ethyl)-5-(7-fluoro-1-isopropyl-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]cinnoline-8 - yl) picolinamide;
7-fluoro-8-(6-(3-(4-fluoropiperidin-1-yl)propoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo [4 ,5-c]cinnolin-2-one;
(S)-7-fluoro-8-(6-(3-(3-fluoropyrrolidin-1-yl)propoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H - imidazo[4,5-c]cinnolin-2-one;
(R)-7-fluoro-8-(6-(3-(3-fluoropyrrolidin-1-yl)propoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H - imidazo[4,5-c]cinnolin-2-one;
8-(6-(3-(3-azabicyclo[3.1.0]hexane-3-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3- dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-(3-(dimethylamino)propoxy)-2-fluoropyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5 -c]cinnolin-2-one;
7-fluoro-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,3- dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-(3-(dimethylamino)propoxy)pyridin-3-yl)-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H - imidazo[4,5-c]cinnolin-2-one;
7-fluoro-3-methyl-8-(6-(3-(pyrrolidin-1-yl)propoxy)pyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,3- dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-(3-((dimethylamino)methyl)pyrrolidin-1-yl)pyridin-3-yl)-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)- 1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-(4-(dimethylamino)piperidin-1-yl)pyridin-3-yl)-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3 - dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-((2-(dimethylamino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3- dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
7-fluoro-8-(6-(3-(4-fluoropiperidin-1-yl)propoxy)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1 ,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
(R)-7-fluoro-8-(6-(3-(3-fluoropyrrolidin-1-yl)propoxy)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4- yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-((2-(diethylamino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c ] cinnolin-2-one;
8-(6-((2-(ethyl(methyl)amino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo [4 ,5-c]cinnolin-2-one;
7-fluoro-1-isopropyl-3-methyl-8-(6-((2-morpholinoethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnoline -2-on;
7-fluoro-1-isopropyl-3-methyl-8-(6-((2-(piperazin-1-yl)ethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo [4 ,5-c]cinnolin-2-one;
7-fluoro-1-isopropyl-3-methyl-8-(6-((2-(4-methylpiperazin-1-yl)ethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H- imidazo[4,5-c]cinnolin-2-one;
8-(6-((2-(4-cyclopropylpiperazin-1-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H - imidazo[4,5-c]cinnolin-2-one;
8-(6-((2-(2-azaspiro[3.3]heptan-2-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3 - dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-((2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl -1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-((2-(2-azaspiro[3.4]octan-2-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3 - dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-((2-(6-azabicyclo[3.2.0]heptan-6-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1 ,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-(3-(diethylamino)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnoline- 2-on;
8-(6-(3-(ethyl(methyl)amino)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5- c] cinnolin-2-one;
7-fluoro-1-isopropyl-3-methyl-8-(6-(3-morpholinopropoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnoline-2- on;
7-fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperazin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5- c] cinnolin-2-one;
7-fluoro-1-isopropyl-3-methyl-8-(6-(3-(4-methylpiperazin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo [4 ,5-c]cinnolin-2-one;
8-(6-(3-(4-cyclopropylpiperazin-1-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo [ 4,5-c]cinnolin-2-one;
8-(6-(3-(2-azaspiro[3.3]heptan-2-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro- 2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-(3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1, 3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-(3-(2-azaspiro[3.4]octan-2-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro- 2H-imidazo[4,5-c]cinnolin-2-one; and
8-(6-(3-(6-azabicyclo[3.2.0]heptan-6-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3- dihydro-2H-imidazo[4,5-c]cinnolin-2-one,
The compound of formula (I) according to [1] above, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
[15] A compound of formula (I) according to any one of [1] to [14] above, or a pharmaceutical compound having an AO intrinsic clearance value of less than 1.8 μL/min/mg of protein in the human liver cytosolic system its salt acceptable to
[16] A pharmaceutical composition comprising the compound of formula (I) or a pharmaceutically acceptable salt thereof according to [1] above and at least one pharmaceutically acceptable excipient.
[17] The pharmaceutical composition of [16] above, which does not contain an agent for promoting blood-brain barrier (BBB) migration.
[18] A method of treating an ATM-related disease or condition in a subject in need thereof, comprising the compound of formula (I) of any of [1] to [15] above or a pharmaceutically acceptable administering to said subject a therapeutically effective amount of a salt thereof.
[19] The method of [18] above, wherein the ATM-related disease or condition is cancer.
[20] the cancer is colorectal cancer, glioblastoma, gastric cancer, ovarian cancer, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, head and neck squamous cell carcinoma, breast cancer, hepatocellular carcinoma; The method according to [19] above, which is selected from the group consisting of small cell lung cancer and non-small cell lung cancer.
[21] The method of [19] above, wherein the cancer is metastatic cancer such as brain metastasis.
[22] The method of [18] above, further comprising administering radiation therapy to said subject concurrently, separately, or sequentially with a compound of formula (I) or a pharmaceutically acceptable salt thereof. .
[23] The method of [22] above, wherein the radiotherapy is brain irradiation.
[24] The method of [22] or [23] above, wherein the ATM-related disease or condition is cancer, preferably glioblastoma.
[25] A method of treating Huntington's disease in a subject in need thereof, comprising: A method comprising administering to said subject a therapeutically effective amount.
[26] The method of [18] or [25] above, wherein the compound is capable of translocating across the blood-brain barrier (BBB) in the absence of an agent for promoting blood-brain barrier (BBB) translocation.
[27] A compound of formula (I) according to any one of [1] to [15] above, or a pharmaceutically acceptable salt thereof, for use in treating an ATM-related disease or condition.
[28] Use of the compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of [1] to [15] above in the manufacture of a medicament for treating an ATM-related disease or condition .
[29] A compound of formula (I) according to any of the above [1] to [15] for use in the treatment of ATM-related diseases or conditions and administered concurrently, separately or sequentially with radiotherapy. or a pharmaceutically acceptable salt thereof.
[30] at least one additional antineoplastic agent selected from the group consisting of doxorubicin, irinotecan, topotecan, etoposide, mitomycin, bendamustine, chlorambucil, cyclophosphamide, ifosfamide, carmustine, melphalan, and bleomycin; A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of [1] to [15] above, administered individually or sequentially.
Claims (27)
(式中、
R1は、水素またはメチルであり;
R2は、イソプロピルであり;
R3は、水素またはフルオロであり;
R4、R5およびR6は、それぞれ水素またはフルオロから独立して選択され;
R7は-L-NR8R9であり、Lは直接的な結合、-(CH2)mO(CH2)n-、または-CONR10(CH2)p-から選択され、前記-(CH2)mO(CH2)n-および前記-CONR10(CH2)p-は場合によっては1または複数のR11により置換されていてもよく;
R8およびR9は、水素、アルキル、アルケニル、アルキニル、飽和または不飽和のシクロアルキル、および飽和または不飽和の複素環式基からなる群からそれぞれ独立して選択され、前記アルキル、アルケニル、アルキニル、飽和または不飽和のシクロアルキル、および飽和または不飽和の複素環式基は場合によっては1または複数のR12により置換されていてもよく;あるいは、
R8およびR9は、それらが結合している窒素原子と一緒になって場合によってはN、O、およびSから選択される1または複数の追加のヘテロ原子を含有していてもよい、且つ、場合によっては1または複数のR13により置換されていてもよい飽和または不飽和の複素環式基を形成し;
R10は、水素、アルキル、シクロアルキル、および炭素結合した飽和または不飽和の複素環式基からなる群から選択され、前記複素環式基は場合によってはN、O、およびSから選択される1または複数の追加のヘテロ原子を含有していてもよく、且つ、場合によっては1または複数のR13により置換されていてもよく;
R11は、水素、ハロゲン、アルキル、シクロアルキル、アルコキシル、並びに、場合によってはN、O、およびSから選択される1または複数の追加のヘテロ原子を含有していてもよい、且つ、場合によっては1または複数のR13により置換されていてもよい飽和または不飽和の複素環式基からなる群から選択され;
R12は、水素、ハロゲン、シアノ、ニトロ、ヒドロキシル、アルキル、アルケニル、アルキニル、およびアルコキシからなる群から選択され;
R13は、アシル、アルキル、アルケニル、アルキニル、アルコキシ、アミド、アミノ、アリール、シアノ、シクロアルキル、ハロゲン、ハロアルキル、ハロアルコキシ、ヘテロアリール、ヒドロキシ、ニトロ、および-(CH2)qNR14R15からなる群から選択され;
R14およびR15は、水素、アルキル、およびシクロアルキルからなる群からそれぞれ独立して選択され;あるいは、
R14およびR15は、それらが結合している窒素原子と一緒になって場合によってはN、O、およびSから選択される1または複数の追加のヘテロ原子を含有していてもよい、且つ、場合によっては1または複数のR16により置換されていてもよい飽和または不飽和の複素環式基を形成し;
R16は、アシル、アルキル、アルケニル、アルキニル、アルコキシ、アミド、アミノ、アリール、シアノ、シクロアルキル、ハロゲン、ハロアルキル、ハロアルコキシ、ヘテロアリール、ヒドロキシ、およびニトロからなる群から選択され;
mは0、1、または2であり;
nは2~4の範囲の整数であり;
pは2~4の範囲の整数であり;並びに、
qは0、1、または2である)。 Compounds of formula (I):
R 1 is hydrogen or methyl;
R 2 is isopropyl ;
R 3 is hydrogen or fluoro;
R 4 , R 5 and R 6 are each independently selected from hydrogen or fluoro;
R 7 is -L-NR 8 R 9 and L is selected from a direct bond, -(CH 2 ) m O(CH 2 ) n -, or -CONR 10 (CH 2 ) p -, said - (CH 2 ) m O(CH 2 ) n — and said —CONR 10 (CH 2 ) p — optionally substituted with one or more R 11 ;
R8 and R9 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, saturated or unsaturated cycloalkyl, and saturated or unsaturated heterocyclic groups, wherein said alkyl, alkenyl, alkynyl , saturated or unsaturated cycloalkyl, and saturated or unsaturated heterocyclic groups optionally substituted by one or more R 12 ;
R8 and R9 , together with the nitrogen atom to which they are attached, optionally contain one or more additional heteroatoms selected from N, O, and S, and , forming a saturated or unsaturated heterocyclic group optionally substituted by one or more R 13 ;
R 10 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, and carbon-bonded saturated or unsaturated heterocyclic groups, said heterocyclic groups optionally selected from N, O, and S optionally containing one or more additional heteroatoms and optionally substituted by one or more R 13 ;
R 11 may contain hydrogen, halogen, alkyl, cycloalkyl, alkoxyl, and optionally one or more additional heteroatoms selected from N, O, and S, and optionally is selected from the group consisting of saturated or unsaturated heterocyclic groups optionally substituted by one or more R 13 ;
R 12 is selected from the group consisting of hydrogen, halogen, cyano, nitro, hydroxyl, alkyl, alkenyl, alkynyl, and alkoxy;
R 13 is acyl, alkyl, alkenyl, alkynyl, alkoxy, amido, amino, aryl, cyano, cycloalkyl, halogen, haloalkyl, haloalkoxy, heteroaryl, hydroxy, nitro, and —(CH 2 ) q NR 14 R 15 selected from the group consisting of;
R 14 and R 15 are each independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl; or
R 14 and R 15 , together with the nitrogen atom to which they are attached, optionally contain one or more additional heteroatoms selected from N, O, and S, and , forming a saturated or unsaturated heterocyclic group optionally substituted by one or more R 16 ;
R 16 is selected from the group consisting of acyl, alkyl, alkenyl, alkynyl, alkoxy, amido, amino, aryl, cyano, cycloalkyl, halogen, haloalkyl, haloalkoxy, heteroaryl, hydroxy, and nitro;
m is 0, 1, or 2;
n is an integer ranging from 2 to 4;
p is an integer ranging from 2 to 4; and
q is 0, 1, or 2 ).
アルキルからそれぞれ独立して選択される、請求項9に記載の式(I)の化合物または薬学的に許容可能なその塩。 R 13 is —(CH 2 ) q NR 14 R 15 and R 14 and R 15 are C 1-6
10. A compound of formula (I) according to claim 9 , or a pharmaceutically acceptable salt thereof, each independently selected from alkyl.
R2がイソプロピルであり;
R3がフルオロであり;
R4、R5、およびR6が水素であり;
R7が-L-NR8R9であり;
Lが場合によっては1または複数のR11により置換されていてもよい-(CH2)mO(CH2)n-であり;
R8およびR9が場合によっては1または複数のR12により置換されていてもよいC1-6アルキルからそれぞれ独立して選択され;あるいは、
R8およびR9がそれらが結合している窒素原子と一緒になって、
R11が水素であり;
R12が水素であり;
R13がハロゲンであり;
mが0、1、または2であり;
nが2~4の範囲の整数である、
請求項1に記載の式(I)の化合物または薬学的に許容可能なその塩。 R 1 is methyl;
R 2 is isopropyl;
R 3 is fluoro;
R 4 , R 5 , and R 6 are hydrogen;
R 7 is -L-NR 8 R 9 ;
L is —(CH 2 ) m O(CH 2 ) n — optionally substituted with one or more R 11 ;
R 8 and R 9 are each independently selected from C 1-6 alkyl optionally substituted by one or more R 12 ; or
R8 and R9 together with the nitrogen atom to which they are attached,
R 11 is hydrogen;
R 12 is hydrogen;
R 13 is halogen;
m is 0, 1, or 2;
n is an integer ranging from 2 to 4;
A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof.
8-(6-(3-(ジメチルアミノ)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-(3-(ピロリジン-1-イル)プロポキシ)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(4-(ジメチルアミノ)ピペリジン-1-イル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-((ジメチルアミノ)メチル)ピロリジン-1-イル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(ジメチルアミノ)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-((2-(ピペリジン-1-イル)エトキシ)メチル)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-((2-(ピロリジン-1-イル)エトキシ)メチル)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
(R)-7-フルオロ-8-(6-((2-(3-フルオロピロリジン-1-イル)エトキシ)メチル)ピリジン-3-イル)-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-8-(6-((2-(4-フルオロピペリジン-1-イル)エトキシ)メチル)ピリジン-3-イル)-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(3-アザビシクロ[3.1.0]ヘキサン-3-イル)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
N-(2-(ジメチルアミノ)エチル)-5-(7-フルオロ-1-イソプロピル-3-メチル-2-オキソ-2,3-ジヒドロ-1H-イミダゾ[4,5-c]シンノリン-8-イル)ピコリンアミド;
7-フルオロ-8-(6-(3-(4-フルオロピペリジン-1-イル)プロポキシ)ピリジン-3-イル)-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
(S)-7-フルオロ-8-(6-(3-(3-フルオロピロリジン-1-イル)プロポキシ)ピリジン-3-イル)-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
(R)-7-フルオロ-8-(6-(3-(3-フルオロピロリジン-1-イル)プロポキシ)ピリジン-3-イル)-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(3-アザビシクロ[3.1.0]ヘキサン-3-イル)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(ジメチルアミノ)プロポキシ)-2-フルオロピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(ジエチルアミノ)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(エチル(メチル)アミノ)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-((2-モルホリノエトキシ)メチル)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-((2-(ピペラジン-1-イル)エトキシ)メチル)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-((2-(4-メチルピペラジン-1-イル)エトキシ)メチル)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(4-シクロプロピルピペラジン-1-イル)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(2-アザスピロ[3.3]ヘプタン-2-イル)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(2-オキサ-6-アザスピロ[3.3]ヘプタン-6-イル)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(2-アザスピロ[3.4]オクタン-2-イル)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-((2-(6-アザビシクロ[3.2.0]ヘプタン-6-イル)エトキシ)メチル)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(ジエチルアミノ)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(エチル(メチル)アミノ)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-(3-モルホリノプロポキシ)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-(3-(ピペラジン-1-イル)プロポキシ)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
7-フルオロ-1-イソプロピル-3-メチル-8-(6-(3-(4-メチルピペラジン-1-イル)プロポキシ)ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(4-シクロプロピルピペラジン-1-イル)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(2-アザスピロ[3.3]ヘプタン-2-イル)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(2-オキサ-6-アザスピロ[3.3]ヘプタン-6-イル)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;
8-(6-(3-(2-アザスピロ[3.4]オクタン-2-イル)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン;および
8-(6-(3-(6-アザビシクロ[3.2.0]ヘプタン-6-イル)プロポキシ)ピリジン-3-イル)-7-フルオロ-1-イソプロピル-3-メチル-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オン、
からなる群から選択される、請求項1に記載の式(I)の化合物または薬学的に許容可能なその塩。 7-fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5- c] cinnolin-2-one;
8-(6-(3-(dimethylamino)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnoline -2-on;
7-fluoro-1-isopropyl-3-methyl-8-(6-(3-(pyrrolidin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5- c] cinnolin-2-one;
8-(6-(4-(dimethylamino)piperidin-1-yl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5 -c]cinnolin-2-one;
8-(6-(3-((dimethylamino)methyl)pyrrolidin-1-yl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo [ 4,5-c]cinnolin-2-one;
8-(6-((2-(dimethylamino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5- c] cinnolin-2-one;
7-fluoro-1-isopropyl-3-methyl-8-(6-((2-(piperidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo [4 ,5-c]cinnolin-2-one;
7-fluoro-1-isopropyl-3-methyl-8-(6-((2-(pyrrolidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo [4 ,5-c]cinnolin-2-one;
(R)-7-fluoro-8-(6-((2-(3-fluoropyrrolidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1-isopropyl-3-methyl-1,3- dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
7-fluoro-8-(6-((2-(4-fluoropiperidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H- imidazo[4,5-c]cinnolin-2-one;
8-(6-((2-(3-azabicyclo[3.1.0]hexan-3-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1 ,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
N-(2-(dimethylamino)ethyl)-5-(7-fluoro-1-isopropyl-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]cinnoline-8 - yl) picolinamide;
7-fluoro-8-(6-(3-(4-fluoropiperidin-1-yl)propoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo [4 ,5-c]cinnolin-2-one;
(S)-7-fluoro-8-(6-(3-(3-fluoropyrrolidin-1-yl)propoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H - imidazo[4,5-c]cinnolin-2-one;
(R)-7-fluoro-8-(6-(3-(3-fluoropyrrolidin-1-yl)propoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H - imidazo[4,5-c]cinnolin-2-one;
8-(6-(3-(3-azabicyclo[3.1.0]hexane-3-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3- dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-(3-(dimethylamino)propoxy)-2-fluoropyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5 -c]cinnolin-2-one ;
8- (6-((2-(diethylamino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c ] cinnolin-2-one;
8-(6-((2-(ethyl(methyl)amino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo [4 ,5-c]cinnolin-2-one;
7-fluoro-1-isopropyl-3-methyl-8-(6-((2-morpholinoethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnoline -2-on;
7-fluoro-1-isopropyl-3-methyl-8-(6-((2-(piperazin-1-yl)ethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo [4 ,5-c]cinnolin-2-one;
7-fluoro-1-isopropyl-3-methyl-8-(6-((2-(4-methylpiperazin-1-yl)ethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H- imidazo[4,5-c]cinnolin-2-one;
8-(6-((2-(4-cyclopropylpiperazin-1-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H - imidazo[4,5-c]cinnolin-2-one;
8-(6-((2-(2-azaspiro[3.3]heptan-2-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3 - dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-((2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl -1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-((2-(2-azaspiro[3.4]octan-2-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3 - dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-((2-(6-azabicyclo[3.2.0]heptan-6-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1 ,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-(3-(diethylamino)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnoline- 2-on;
8-(6-(3-(ethyl(methyl)amino)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5- c] cinnolin-2-one;
7-fluoro-1-isopropyl-3-methyl-8-(6-(3-morpholinopropoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnoline-2- on;
7-fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperazin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5- c] cinnolin-2-one;
7-fluoro-1-isopropyl-3-methyl-8-(6-(3-(4-methylpiperazin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo [4 ,5-c]cinnolin-2-one;
8-(6-(3-(4-cyclopropylpiperazin-1-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo [ 4,5-c]cinnolin-2-one;
8-(6-(3-(2-azaspiro[3.3]heptan-2-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro- 2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-(3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1, 3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;
8-(6-(3-(2-azaspiro[3.4]octan-2-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro- 2H-imidazo[4,5-c]cinnolin-2-one; and 8-(6-(3-(6-azabicyclo[3.2.0]heptan-6-yl)propoxy)pyridin-3-yl) -7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one,
2. A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
27. Use according to claim 18 or 26 , wherein said compound is capable of translocating across the blood-brain barrier (BBB) in the absence of an agent for promoting blood-brain barrier (BBB) translocation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024017316A JP2024054247A (en) | 2018-09-14 | 2024-02-07 | 1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one and its uses as selective modulators of ataxia telangiectasia mutated (atm) kinase - Patents.com |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018105675 | 2018-09-14 | ||
CNPCT/CN2018/105675 | 2018-09-14 | ||
PCT/CN2019/105951 WO2020052688A1 (en) | 2018-09-14 | 2019-09-16 | 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-c] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024017316A Division JP2024054247A (en) | 2018-09-14 | 2024-02-07 | 1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one and its uses as selective modulators of ataxia telangiectasia mutated (atm) kinase - Patents.com |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022500428A JP2022500428A (en) | 2022-01-04 |
JPWO2020052688A5 true JPWO2020052688A5 (en) | 2022-09-30 |
JP7436465B2 JP7436465B2 (en) | 2024-02-21 |
Family
ID=69777300
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021514039A Active JP7436465B2 (en) | 2018-09-14 | 2019-09-16 | 1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5] as a selective modulator of ataxia telangiectasia mutated (ATM) kinase -c] Cinnolin-2-one and its use |
JP2024017316A Pending JP2024054247A (en) | 2018-09-14 | 2024-02-07 | 1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one and its uses as selective modulators of ataxia telangiectasia mutated (atm) kinase - Patents.com |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024017316A Pending JP2024054247A (en) | 2018-09-14 | 2024-02-07 | 1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one and its uses as selective modulators of ataxia telangiectasia mutated (atm) kinase - Patents.com |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220047595A1 (en) |
EP (1) | EP3849984A4 (en) |
JP (2) | JP7436465B2 (en) |
KR (1) | KR20210061337A (en) |
CN (2) | CN112752758B (en) |
AU (1) | AU2019339006B2 (en) |
CA (1) | CA3111994A1 (en) |
WO (1) | WO2020052688A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021433713A1 (en) * | 2021-03-17 | 2023-09-28 | Suzhou Zanrong Pharma Limited | Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof |
GB202114704D0 (en) * | 2021-10-14 | 2021-12-01 | Univ Birmingham | ATM inhibition |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO2714752T3 (en) | 2014-05-08 | 2018-04-21 | ||
GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
GB201519406D0 (en) | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
GB201519568D0 (en) | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
CN108884084A (en) * | 2016-03-21 | 2018-11-23 | 阿斯利康(瑞典)有限公司 | Cinnolines -4- amine compounds and its purposes in treating cancer |
GB201608227D0 (en) | 2016-05-11 | 2016-06-22 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
CN111344293A (en) * | 2017-09-20 | 2020-06-26 | 阿斯利康(瑞典)有限公司 | 1, 3-dihydroimidazo [4, 5-c ] cinnolin-2-one compounds and their use in the treatment of cancer |
-
2019
- 2019-09-16 CN CN201980060250.5A patent/CN112752758B/en active Active
- 2019-09-16 CN CN202211142049.1A patent/CN115636833A/en active Pending
- 2019-09-16 WO PCT/CN2019/105951 patent/WO2020052688A1/en unknown
- 2019-09-16 AU AU2019339006A patent/AU2019339006B2/en active Active
- 2019-09-16 CA CA3111994A patent/CA3111994A1/en active Pending
- 2019-09-16 JP JP2021514039A patent/JP7436465B2/en active Active
- 2019-09-16 EP EP19860219.5A patent/EP3849984A4/en active Pending
- 2019-09-16 US US17/274,781 patent/US20220047595A1/en active Pending
- 2019-09-16 KR KR1020217006022A patent/KR20210061337A/en unknown
-
2024
- 2024-02-07 JP JP2024017316A patent/JP2024054247A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7146016B2 (en) | Compounds and compositions for inhibiting the activity of SHP2 | |
ES2805232T3 (en) | Compounds and compositions to inhibit SHP2 activity | |
CN107864625B (en) | Combination products containing substituted 2, 3-dihydroimidazo [1,2-c ] quinazolines | |
CN111201223A (en) | Octahydrocyclopenta [ c ] pyrrole allosteric inhibitors of SHP2 | |
TW201701879A (en) | Combinations of IRAK4 inhibitors | |
JP7208659B2 (en) | Use of Indolinone Compounds | |
CA2506308A1 (en) | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | |
US11702427B2 (en) | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | |
JP2011503063A5 (en) | ||
WO2010031265A1 (en) | Pharmaceutical composition for the treatment of proliferative diseases | |
JP2019048822A (en) | Use of 2-carboxamide cycloamino urea derivatives in treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members | |
TW202003487A (en) | Substituted 2,2’-bipyrimidinyl compounds, analogues thereof, and methods using same | |
US20210393624A1 (en) | Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
JPWO2020052688A5 (en) | ||
CN110642910B (en) | Thymidine derivative and preparation method and application thereof | |
JP2023526283A (en) | Monotherapy and combination therapy | |
US11684672B2 (en) | Combinations of copanlisib with anti-PD-1 antibody | |
EP3973963A1 (en) | Quinoline derivatives for treatment of head and neck cancer | |
CA3116137A1 (en) | Tlr7 agonist for treating colorectal cancer and pharmaceutical combination thereof | |
KR20240055778A (en) | Pharmaceutical combinations comprising TEAD inhibitors and their use for the treatment of cancer | |
CN117835978A (en) | Pharmaceutical combinations comprising TEAD inhibitors and their use for cancer treatment | |
TWI671083B (en) | Pharmaceutical formulation | |
TWI528960B (en) | Pharmaceutical composition for the treatment of proliferative diseases | |
WO2019105835A1 (en) | Combinations of copanlisib and anetumab ravtansine |